Last update 24 Mar 2025

Oxaliplatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Dendrimer-Oxaliplatin (Starpharma), Diaminocyclohexane Oxalatoplatinum, GSOX
+ [34]
Target
Action
inhibitors
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
China (01 Jan 2000),
RegulationAccelerated Approval (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC8H14N2O4Pt
InChIKeyZROHGHOFXNOHSO-BNTLRKBRSA-L
CAS Registry61825-94-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small intestine carcinoma
Japan
21 Sep 2018
Stomach Cancer
Japan
20 Mar 2015
Pancreatic Cancer
Japan
20 Dec 2013
Colorectal Cancer
United States
10 Jan 2007
Advanced Colorectal Adenocarcinoma
Australia
28 Nov 2006
Colonic Cancer
United States
09 Aug 2002
Rectal Cancer
United States
09 Aug 2002
Neoplasms
China
01 Jan 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RAS Wild Type Colorectal CancerPhase 3
France
30 Oct 2013
RAS Wild Type Colorectal CancerPhase 3
Ireland
30 Oct 2013
RAS Wild Type Colorectal CancerPhase 3
Israel
30 Oct 2013
Advanced gastric carcinomaPhase 3
South Korea
30 Dec 2011
colon cancer liver metastasisPhase 3
China
01 Jan 2008
Advanced Hepatocellular CarcinomaPhase 3
China
01 Mar 2007
Advanced Hepatocellular CarcinomaPhase 3
South Korea
01 Mar 2007
Advanced Hepatocellular CarcinomaPhase 3
Taiwan Province
01 Mar 2007
Advanced Hepatocellular CarcinomaPhase 3
Thailand
01 Mar 2007
Metastatic colon cancerPhase 3
United States
01 Dec 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
38
onrrbvstvv = fbpbxoktbz bvzujwtfwy (elmluqesca, rchyszryql - asrmbqdpxg)
-
25 Feb 2025
Not Applicable
-
Lenvatinib plus FOLFOX-HAIC
jgezzpuuaa(kbovicsugc) = Grade 3-4 adverse events, including nausea, vomiting, diarrhea, thrombocytopenia, and neutropenia, were more prevalent in the lenvaHAIC group scvcfwrcxx (glnmenwgxg )
Positive
23 Jan 2025
Phase 1/2
40
Docetaxel 60 mg/m²
gwklhsvyxl(dnzdprtsyx) = tfopfowosu pbpgmliauo (qhnmsuzwlg )
Positive
23 Jan 2025
S-1 120 mg/body
ckamoxbnmr(ehflmeyzgd) = xireaerdhm rtrcwzwzus (omutajpbjx )
Phase 2
54
Neoadjuvant FLOT therapy
zeztljzkcc(qwbiljnzzj) = ubpbasewkc cnmwbhrijf (kkqdmstovj, 29.8 - 57.7)
Positive
23 Jan 2025
Phase 3
525
3-month mFOLFOX6/CAPOX treatment
dupdfjbiwm(vludaccsus) = The incidence of long-lasting PSN was significantly lower at 3 months than at 6 months of therapy rgjxqpknzg (xqdpnlrhot )
Positive
23 Jan 2025
6-month mFOLFOX6/CAPOX treatment
Phase 1
14
Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B)
pgwtsunyjk(ejqzytlaot) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism jbzdayzwbt (oolfakkppj )
Positive
23 Jan 2025
Phase 3
Colorectal Liver Metastases
Adjuvant
RAS/BRAF mutations | positive postoperative ctDNA methylation
92
Standard systemic chemotherapy only
uprdgvyqod(znzayduylv) = fjenkllwfs aadkapmcrz (ufcpvwfedy )
Positive
01 Jan 2025
Standard systemic chemotherapy + HAI-FUDR
uprdgvyqod(znzayduylv) = tyakcmyzmc aadkapmcrz (ufcpvwfedy )
Phase 2
52
CAPOX/CAPIRI plus bevacizumab
vbdospimkr(buxyiznrno) = bqclsyttmi bzwblnomwi (qjpezqtbjs, 9.0 - 12.4)
Positive
11 Dec 2024
Phase 2
46
Leucovorin, Oxaliplatin, Docetaxel, S-1 (LOTS)
feqxyihqbs(cnygqslrsx) = ygoqoqqcwm zaprlykyfm (yggpemzawc )
Positive
07 Dec 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free